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Abstract: Children who appear healthy, even if they have one or more recognized cardiovas-
cular risk factors, do not generally have outcomes of cardiovascular or other vascular disease 
during childhood. Historically, pediatric medicine has not aggressively screened for or treated 
cardiovascular risk factors in otherwise healthy children. However, studies such as the P-Day 
Study (Pathobiological Determinants of Atherosclerosis in Youth), and the Bogalusa Heart 
Study, indicate that healthy children at remarkably young ages can have evidence of signifi-
cant atherosclerosis. With the increasing prevalence of pediatric obesity, can we expect more 
health problems related to the consequences of pediatric dyslipidemia, hypertriglyceridemia, 
and atherosclerosis in the future? For many years, medications have been available and used 
in adult populations to treat dyslipidemia. In recent years, reports of short-term safety of some 
of these medications in children have been published. However, none of these studies have 
detailed long-term follow-up, and therefore none have described potential late side-effects of 
early cholesterol-lowering therapy, or potential benefits in terms of reduction of or delay in 
cardiovascular or other vascular end-points. In 2007, the American Heart Association published 
a scientific statement on the use of cholesterol-lowering therapy in pediatric patients. In this 
review paper, we discuss some of the current literature on cholesterol-lowering therapy in 
children, including the statins that are currently available for use in children, and some of the 
cautions with using these and other cholesterol-lowering medications. A central tenet of this 
review is that medications are not a substitute for dietary and lifestyle interventions, and that 
even in children on cholesterol-lowering medications, physicians should take every opportunity 
to encourage children and their parents to make healthy diet and lifestyle choices.
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Background
In 1961, atherosclerosis was described by Holman as “a pediatric problem”,1 recogniz-
ing that atherosclerosis, associated typically with adults, has its origins in the pediatric 
age range. The P-Day Study, or Pathobiological Determinants of Atherosclerosis in 
Youth Study, is a multi-center postmortem study in youth, 15 to 34 years old, following 
death by trauma, homicide, or suicide,2 where traditional cardiovascular risk factors 
were estimated in the 48 hours following death. This study demonstrated conclusively 
that cardiovascular risk factors such as hypercholesterolemia and hypertension were 
associated with the size of arterial fatty streaks and fibrous plaques in youth.2,3 Prior 
to this landmark study, postmortem studies of young soldiers during the Korean 
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war4 and the Vietnam war5 found postmortem evidence 
of atherosclerosis in youth who had been perceived to be 
healthy before sudden death during war. During the  Vietnam 
war specifically, of 105 soldiers who died, at a mean age 
of 22 years, 45% and 5% of soldiers had gross evidence 
of some or severe coronary atherosclerosis, respectively.5 
The Bogalusa Heart Study included both epidemiological 
and opportunistic pathological studies, and found that both 
coronary and aortic fatty streaks in 35 autopsied subjects 
were positively associated with low-density lipoprotein cho-
lesterol (LDLc) and negatively associated with high-density 
lipoprotein cholesterol (HDLc) measured during life.6 In its 
pathological study, the Bogalusa investigators found that the 
prevalence of fatty streaks and fibrous plaques were 50% 
and 8%, respectively, during childhood, and 69% and 85%, 
respectively, during young adulthood.7 Thus, these studies 
have supported Holman’s claim,1 that atherosclerosis can 
begin in childhood.
While pathology studies are important and have yielded 
much valuable information, identifying early evidence of 
atherosclerosis and vascular disease in vivo, in children 
at young ages, before the end-points of atherosclerosis 
manifest is a preferred strategy. Ultrasound may be used, in 
a standardized manner, to assess the thickness of the carotid 
intima-media layer, as this thickness is positively associated 
with various cardiac risk factors,8 as well as with clusters of 
risk factors.9 Ultrasound can also be used to assess arterial 
function, including distensibility, stiffness, and vasodilation. 
Children with familial hypercholesterolemia have increased 
carotid artery stiffness, independent of their blood pressure.10 
Impaired fitness and overweight are associated with vascu-
lar dysfunction,11 which, in turn, in the obese population is 
associated with decreased insulin sensitivity12 and vascular 
dysfunction.13 Additionally, children with type 1 diabetes 
mellitus have been shown to have vascular dysfunction 
using several different measures of vascular function,14,15 
including pulse wave velocity.16 Identifying a positive family 
history of early ischemic heart disease, without additional 
known risk factors in children, is associated with impaired 
vascular function in children.10 For adults, the results of the 
Framingham heart study have led to the development of the 
Framingham risk score, which can be used to cumulate an 
individual’s risk factors, and predict that individual’s risk of 
developing ischemic heart disease over time. Recently, a not 
dissimilar risk score was developed for pediatric patients.17 
This tool accurately predicts advanced atherosclerotic lesions 
noted at autopsy. Further clinical and epidemiological stud-
ies are required for validation, but it may prove a useful tool 
for screening, treating, communicating with patients, and 
translating risks for individual patients.
In the last 3 decades, the incidence of pediatric obesity 
in the USA has tripled. Furthermore, the TODAY Study 
(Treatment Options for type 2 Diabetes in Adolescents and 
Youth Study) suggests that, of type 2 diabetes mellitus pedi-
atric patients, who are obese at presentation, up to 60% have 
dyslipidemia, and 17% have hypertension at presentation.18 It 
is worth noting that hypertriglyceridemia is the dyslipidemia 
primarily associated with obesity. When Holman described 
atherosclerosis as a pediatric problem,1 he referred largely to 
children with primary, or monogenic, causes of hypercholes-
terolemia – children with conditions such as familial hyper-
cholesterolemia. Currently, the numbers of children with 
hypercholesterolemia reflect largely an increase in those with 
secondary hypercholesterolemia, especially hyperlipidemia 
secondary to obesity.19 This reflects a paradigm shift in the 
etiology of hypercholesterolemia in children and adolescents. 
But has there been a parallel paradigm shift in our approach 
to therapy in these children?
Principles of medication use  
in children with dyslipidemia
The initiation of cholesterol-lowering therapy, as with any 
new therapy, in an individual patient should be accompanied 
by knowledge of the desired end-point or surrogate marker 
of that end-point, ie, reduction in cholesterol or reduction in 
cardiovascular or vascular disease events. For cholesterol-
 lowering, there are recommended levels of cholesterol to 
aim for when starting cholesterol-lowering therapies.19 
Dyslipidemia is a recognized risk factor for cardiovascu-
lar and vascular disease, and has a recognized role in the 
pathophysiology of cardiovascular and vascular disease. 
However, the final end-points of vascular and cardiovascu-
lar disease are rarely seen in normal childhood, and so, in 
pediatrics, surrogate markers are required to replace these 
end-points. Evidence supports the role of statins in both 
primary and secondary prevention of ischemic heart disease 
in adult patients, and this evidence has been extrapolated 
from adult studies to pediatric patients. The longest dura-
tion of follow-up in the studies of statins in children is only 
2 years.20 Studies in pediatric populations demonstrate an 
improvement in vascular function with statin therapy in 
children with heterozygous familial hypercholesterolemia 
(heFH). One such study demonstrated an improvement 
in flow-mediated dilatation with 28 weeks of simvastatin 
therapy.21 Another study demonstrated an improvement 
in carotid intima-media thickness (CIMT) with 2 years of 
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pravastatin therapy.20 Both studied pediatric patients with 
familial hypercholesterolemia. But, flow-mediated dilatation 
and CIMT are only surrogate markers for atherosclerosis. 
Unless we support large multi-center randomized controlled 
trials (RCTs), with long-term follow-up, we may never have 
data on the efficacy of our pediatric vascular disease preven-
tion measures when our patients reach adulthood. If we con-
tinue to start statins, and other cholesterol-lowering therapy, 
in children, without long-term evidence of vascular disease 
prevention, we may never be able to gather this evidence. 
However, given the evidence we have to date on the likelihood 
of vascular disease prevention, in high-risk patients, such as 
those with heFH, it is probably unethical to withhold therapy 
from these children. In this case, long-term epidemiological 
studies are required to gather evidence.
In 2007, the American Heart Association (AHA) pub-
lished a scientific statement on the drug therapy of high-risk 
lipid abnormalities in children and adolescents,19 recom-
mending drug therapy for high-risk lipid abnormalities in 
children as young as 8 years old, and specifically starting 
therapy with a statin medication. This sparked discussion 
in the pediatric medical community on the potential risks 
and benefits of statin therapy in children. Subsequently, the 
AHA statement was endorsed by the American Academy of 
Pediatrics (AAP).22
There is mounting evidence of truth in Holman’s words, 
that atherosclerosis is “a pediatric problem”.1 It appears that 
this truth is even truer today, with our current and increas-
ing problems with pediatric obesity, while acknowledging 
that our clinical end-points for treating hyperlipidemia in 
children are limited by the fact that our patients are children. 
This invited review aims to describe the current options and 
controversies in the pharmacological therapies available for 
pediatric hyperlipidemia.
Primary versus secondary 
hyperlipidemia and high-risk 
conditions
Hyperlipidemia may be primary, when it occurs as a main 
feature of the primary disease causing hyperlipidemia, or 
secondary, when it occurs as a consequence of a related 
disease, disorder, or treatment. Primary hyperlipidemia 
may occur in children with genetic conditions that cause 
hyperlipidemia. Examples of these include homozygous 
familial hypercholesterolemia (hoFH) and heFH, familial 
hypertriglyceridemia, familial combined hyperlipidemia, and 
dysbetalipoproteinemia. It is worth noting that some of these 
causes of primary hyperlipidemia only manifest in childhood 
if driven by obesity and/or diabetes. They may therefore, in 
fact, be seen as secondary lipid disorders when they occur in 
childhood. In fact, at any step in the pathway to synthesis of 
cholesterol, a mutation may result in dyslipidemia.23 Studies 
on populations of children with heFH comprise a significant 
proportion of data available on the treatment and results of 
cholesterol-lowering in pediatric age patients.
The prevalence of secondary hyperlipidemia, or hyperlipi-
demia or dyslipidemia occurring as a consequence of a dis-
ease, disorder, or therapy has increased significantly in recent 
years, as the prevalence of the related diseases, disorders, and 
therapies has increased. Examples of diseases and disorders 
associated with dyslipidemia include diabetes mellitus (both 
type 1 and type 2), renal failure, hypothyroidism, and liver 
failure. Examples of medications that predispose to dyslipi-
demia include glucocorticoids, retinoids (for example, for 
use in patients with acne), beta-blockers, and anti-retroviral 
therapies.24 In recent years, arguably the single biggest con-
tributor to the increased prevalence of dyslipidemia is the 
increase in childhood obesity, with complications, including 
the metabolic syndrome and with hypertrygliceridemia as 
the specific lipid abnormality associated with insulin resis-
tance. In one recent study, predefined cutoffs for abnormal 
LDLc levels were applied to almost 10,000 children from 
the NHANES (National Health and Nutrition Examination 
Survey) 1999–2006 cohort, and 5.2% to 6.6% of included 
adolescents had abnormal LDLc levels.25
With many possible etiologies for dyslipidemia, it makes 
sense that clinicians should exercise caution when interpret-
ing the results of cholesterol-lowering therapy in one popula-
tion of patients, prior to assuming these same results might 
or would apply to another population of patients.
The AHA 200719 statement suggested that some condi-
tions should be regarded as high-risk conditions, and that if 
a child with a high-risk condition has hyperlipidemia, that 
prompt treatment with pharmacological therapy should be 
considered. The definitions of hyperlipidemia are given in 
the AHA statement.19 Examples of these high-risk condi-
tions include:
• Male gender;
• Strong family history of early vascular or cardiovascular 
disease;
• Low HDLc, high triglycerides (TG), and high small dense 
LDLc;
• Overweight or obesity, and other components of the 
metabolic syndrome;
• Simultaneous diagnosis of other conditions, for example, 
diabetes, hypertension, survivors of childhood cancer, 
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diabetes, HIV infection, history of organ transplantation, 
and systemic lupus erythrematosus;
• Smoking, or passive exposure to smoke;
• Simultaneous presence of newer risk factors or markers for 
vascular and cardiovascular disease, including increased 
lipoprotein (a), homocysteine, C-reactive protein.
The AHA recommends considering starting therapy after 
the age of 10 years, and after Tanner II puberty in males, or 
after 10 years and after menarche in females. However, for 
children who are considered high risk, and who fulfill the 
above criteria, the AHA recommends considering starting 
therapy after the age of 8 years rather than after the age of 
10 years.19
Screening for hyperlipidemia: 
universal versus targeted screening
The AHA 200719 position statement endorses targeted, as 
opposed to universal, screening for hyperlipidemia, citing 
that children with hyperlipidemia, who do not have a fam-
ily history of early cardiovascular disease are considered 
to be at low risk, and therefore should probably not start 
medications for hyperlipidemia until at least adulthood. 
Therefore, targeted screening was recommended for children 
with any of:
1. A family history of parental or grand-parental vascular 
disease at less than 55 years of age. Vascular diseases 
cited include coronary artery disease, peripheral vascular 
disease, cerebrovascular disease, a coronary artery pro-
cedure, myocardial infarction, or sudden cardiac death;
2. A family history of increased total cholesterol 
(.6.2 mmol/L). The recommendation is that these chil-
dren should be screened with fasting total cholesterol 
measurements;
3. Overweight or obesity. If hyperlipidemia is identified, 
these children should then also be screened for other 
elements of the metabolic syndrome.
In 1998, the AAP published recommendations on 
screening for hypercholesterolemia in children.26 Failure 
to identify accurately parental history of hypercholester-
olemia or cardiovascular disease may result in inappropriate 
screening and poor results for targeted screening. Targeting 
children of parents with premature vascular disease may 
be more effective. One such study identified parents who 
had early (ie, at less than 55 years old) myocardial infarc-
tions, and were attending cardiovascular rehabilitation for 
secondary prevention. The authors found prevalences of 
7/82 (8.5%) and 17/82 (20.7%) for high (.3.35 mmol/L, 
or .130 mg/dL) and borderline-high (.2.85 mmol/L, or 
.130 mg/dL) LDLc respectively.27 In 2010, the CARDIAC 
project results of a study on over 20,000 children suggested 
that universal screening is better than targeted screening.28 
It identified that 28.6% of its study population did not meet 
National Cholesterol Education Program Expert Panel on 
Blood Cholesterol Levels in Children and Adolescents 
(NCEP) screening guidelines for dyslipidemia, but, of 
these, 9.5% (N = 548) had dyslipidemia and 1.7% (N = 98) 
required therapy for dyslipidemia. It is possible that the 
better results were due to poor selection of children for 
targeted screening in other studies. Nonetheless, on balance, 
these studies suggest that targeted screening for pediatric 
dyslipidemia misses some children at risk, and clinicians 
should be aware of this.
The AAP published new recommendations on screening 
for pediatric hyperlipidemia in 2008,22 following the AHA 
statement published in 2007.19 These new AAP recommenda-
tions suggest that targeted screening for hyperlipidemia in 
children should be performed using a full fasting lipid profile 
every 3 to 5 years, beginning at age 2 years, using age and 
gender-specific norms for interpreting results (and consider-
ing results .95th percentile as abnormal). The triggers for 
initiating targeted screening include:
1. a positive family history of early atherosclerosis;
2. a positive family history of high cholesterol;
3. an unknown family history;
4. taking into consideration other risk factors individual to 
the child.
The first 2 recommendations for targeted screening 
endorse the AHA statement.19 The remainder of the recom-
mendations provides some clarity in unknown circumstances, 
and accounts for the child without a family history.
Therapeutic options
This review paper addresses pharmacological therapeutic 
options, after diet and exercise have failed, but healthy 
diet and lifestyle choices must be “prescribed”, encour-
aged, and reinforced constantly, concurrent with pharma-
cological therapy. Additionally, both dietary and lifestyle 
modifications should be undertaken by the entire family, 
and not just by the index pediatric case. As with all ado-
lescent medical encounters, the opportunity should also 
be taken to encourage avoidance of cigarette smoking and 
alcohol consumption, and use of contraception. The latter 
is especially true if cholesterol-lowering pharmacological 
interventions are being considered or prescribed, due to 
potential teratogenicity. While we believe that they may 
have added value, a discussion of the potential benefits of 
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nonpharmacological substances, ie, nutraceuticals, such 
as plant sterols and psyllium, is beyond the scope of this 
text. Finally, particularly with the recognized increase in 
dyslipidemia secondary to obesity, clinicians need to be 
particularly aware of the need to treat the primary cause 
of dyslipidemia, ie, weight reduction for obesity.
Therapeutic options: diet
Firstly, as with all pediatric dietary interventions, dietary 
modifications for dyslipidemia must be instituted for the 
entire family, and therefore for the child in the context of 
family therapy. For high-risk individuals, and for motivated 
low-risk individuals, recommended dietary guidelines 
include a balanced caloric intake, a diet high in wholegrains, 
fish, fruit, and vegetables, low in salt and sugar-added 
products, and choosing low-fat dairy produce – a so-called 
“heart-healthy” diet. Individuals with secondary dyslipi-
demia may benefit significantly from such dietary guidelines, 
even more so than individuals with primary, or monogenic, 
hypercholesterolemia.24 However, these guidelines should 
be shared with all patients and their parents, and both par-
ties encouraged to follow them together. The debate on 
statin therapy, and the safe age at which to start therapy for 
dyslipidemia, is ongoing.29,30 With this in mind, following 
guidelines such as these may be of particular importance 
and benefit to younger patients with dyslipidemia, in 
whom there are more concerns about the safety of statin 
therapy. The AHA has new dietary guidelines, called the 
Therapeutic Lifestyle Changes (TLCs), which summarize 
and are based on the above principles, and which replace 
the previous Step I and Step II diets. The pediatric-specific 
information on these new dietary guidelines was published 
in 2005,31 and was subsequently endorsed by the AAP.32 Full 
information for parents and pediatricians is available on the 
AHA website.33
The 2008 AAP position statement by the AAP Committee 
on Nutrition22 included guidelines on diet for dyslipidemia, 
and these were expanded based on the previous 1998 AAP 
guidelines.26 The pertinent changes in the new guidelines 
include:
1. initiation of nutritional therapy, with low-fat milk prod-
ucts, at age 1 year in children at risk due to obesity or 
family history of obesity-related complications;
2. saturated fat and trans fat to comprise ,7% and ,1% of 
the daily dietary caloric intake, respectively;
3. dietary cholesterol intake limited to ,200 mg/day;
4. fiber intake recommended to be at least equal to the 
child’s age in years, plus 5, up to 20 g/day. (For example, 
a 2- year-old child’s fiber intake should be 7 g/day mini-
mum; a 7 year old’s should be 12 g/day minimum; and 
from the age of 15 years, fiber intake should be 20 g/
day.)
A more exhaustive comparison between these guidelines 
is given in Table 1.30
Notwithstanding the ability of a heart-healthy diet to 
reduce cholesterol levels, it has not been proven that dietary 
treatment in childhood reduces atherosclerosis, and vas-
cular and cardiovascular disease in adult life.34 However, 
this systematic review and meta-analysis was based on 
published and unpublished RCTs of dietary intervention 
in pediatric patients with familial hypercholesterolemia. 
Again, it is not necessarily true that the data from this 
study can be extrapolated to patients with secondary dys-
lipidemia, or dyslipidemia from other etiologies. Further 
studies, in other patient populations, are required. In the 
interim, care must be exercised, and heart-healthy diets 
should be recommended to high-risk patients. Following 
a low-fat diet is recommended from the age of 1 year in 
at-risk patients.22 Heart-healthy diets may confer benefits 
beyond cholesterol reduction, for example caloric reduc-
tion may help with weight loss and improve insulin sen-
sitivity, and salt reduction may improve control of blood 
pressure.
Therapeutic options: lifestyle
Similar to dietary changes, lifestyle changes must be insti-
tuted for the entire family, and therefore for the child in the 
context of family therapy. Data from adult studies demon-
strate clinically relevant improvements in cholesterol, and 
other measures, following intensive combined exercise pro-
grams and dietary education and guidelines. Improvements 
in cholesterol, blood pressure, weight, and various other 
measures contribute to improved vascular risk profiles in 
adults. Some similar data exist in pediatric populations35 
leading to a recommendation of tailored exercise programs 
for children. Further data to substantiate this recommen-
dation are required. Specific recommendations from the 
AAP include: 1) limiting screen time (including television, 
computer, game screen time) to 120 minutes per day for all 
children more than 2 years old;36 and 2) no screen time for 
all children less than 2 years old.36 The 2008 Committee on 
Nutrition AAP statement recommends that physical activ-
ity should be encouraged, specifically as a treatment for 
weight management, for hypertriglceridemia, and for low 
HDLc.22 The initial purpose of limiting screen time was to 
protect neurocognitive development, but another advantage 
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of this screen time limit is increased time available for 
activity. Studies support the view that screen time and weight 
and dysmetabolism are positively associated,37–39 but not all 
screen time is equally  obesogenic.40 Active screen time, for 
example, using interactive computerized sports and activi-
ties, so-called “exer-gaming”, may feature in future exercise 
recommendations for children, given that exer-gaming can 
decrease the decline in activity levels during childhood.41 
Exer-gaming has been the focus of several small RCTs,42–44 
but in the future, we expect that it will be studied in far 
greater detail. In one of these studies, for example, children 
randomized to an exer-game intervention played fewer 
overall video games than controls, but more exer-games than 
controls, and had higher accelerometer-measured activity 
than controls.41 A recent joint initiative has been launched 
between manufacturers of exer-games and the AHA to 
encourage activity in youth, and in adults,33 but the outcomes 
are not yet available. While current Canadian guidelines 
recommend at least 90 minutes per day of physical activity 
for all children,45 in 2005, it was documented that up to 90% 
of children are not achieving these targets.46 Additionally, 
the AHA recommends exercise as part of its TLCs diet.33 
Ongoing studies of the benefits of exercise to children 
are required. But pediatricians should include routine but 
tailored recommendations on simultaneous exercise and 
diet for all children, and these recommendations should be 
offered to the family, and to the child as a member of the 
family.
Table 1 Comparison of AAP Recommendations on Hypercholesterolmia in 1998 and 2008
Recommendation 1998 2008
Screening
Measure nonfasting total cholesterol or fasting  
lipids according to algorithm
Assess fasting lipid profile
Recommended with family history of high  
cholesterol or early atherosclerosis
(Unchanged)
Optional with unknown family history Recommended with unknown family history
Optional given personal risk factors Recommended given personal risk factors. Screen 
every 3–5 yr beginning at 2 yr of age
Use same cutoff point? for all ages  
and both sexes
Use age- and sex-specific cholesterol norms 
(>95th percentile considered abnormal)
No specific recommendations for high  
triglyceride levels and low HDL cholesterol levels
Measure triglyceride and HDL cholesterol levels, 
with age- and sex-specific norms
Diet and exercise
Begin nutritional therapy at 2 yr of age Begin nutritional therapy with reduced-fat milk at 
1 yr for children at risk owing to obesity or family
 initiate treatment with NCeP Step-One Diet  
(total fat 20 to 30% of total calories consumed,  
saturated fat <10%, dietary cholesterol <300 mg/day);  
if diet is not effective after 3 mo, progress to Step-Two  
Diet: (total fat 20 to 30%, saturated fat <7%, dietary  
cholesterol <200 mg/day] 
Follow Dietary Guidelines for Americans, 
with saturated fat <7%, trans fat <1%, dietary 
cholesterol <200 mg/day, and suggested fiber 
intake equal to child’s age plus 5 g/day, up to 20 
g/day at 15 yr of age
encourage regular exercise encourage physical activity for weight 
management and for treatment of high 
triglyceride levels and low HDL cholesterol levels
Pharmacology
Use bile acid-binding agents as first-line agent;  
stations not recommended
Include statins among potential first-line agents
10-yr minimum age for pharmacotherapy 8-yr minimum age for pharmacotherapy
initiate pharmacotherapy for LDL cholesterol  
level of ≥190 mg per deciliter or ≥160 mg per  
deciliter with positive family history or 2  
additional risks
Use new LDL cholesterol treatment cutoff point 
of ≥130 mg per deciliter if diabetes mellitus 
present
Notes: Copyright © 2008. Massachusetts Medical  Society.  All rights reserved.  Reprinted with permission from de Ferranti S, Ludwig DS. Storm over statins–the 
controversy  surrounding pharmacologic treatment of children. N Engl J Med. 2008;359(13):1309–1312.30
Abbreviations: AAP, American Academy of Pediatrics; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NCeP, National Cholesterol education Program.
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Therapeutic options: 
pharmacological agents
Statins
Statins are also known as 3-hydroxy-3-methylglutaryl-
coenzyme A (HMG-CoA) reductase inhibitors, so named as 
they act by inhibiting the enzyme HMG-CoA. While a full 
review of the cholesterol biosynthesis pathway is beyond the 
scope of this review, this enzyme is essential in the synthesis 
of cholesterol. Figure 1 describes graphically the steroid syn-
thesis pathway, and indicates the numerous potential effects 
of inhibition of this pathway.30 Inhibition of the HMG-CoA 
enzyme by statins decreases LDLc by 2 mechanisms: it 
decreases de novo cholesterol synthesis; and simultaneously 
increases the synthesis of the LDL receptor by the liver, thus 
increasing clearance of LDLc.
The Food and Drug Administration (FDA) currently 
approves some statins for use in pediatric age range 
patients. Some statins are approved for children over 
8 years of age, others only from 10 years of age.47 Approved 
statins include simvastatin, atorvastatin,  pravastatin, 
 fluvastatin,  rosuvastatin, and lovastatin. However, 
 maximum adult doses of statins are not approved in pedi-
atric patients. All statins recommended by the FDA are 
approved for children with familial hypercholesterolemia, 
and some for other genetic or primary causes of dyslipi-
demia, depending on the populations in which the original 
studies were conducted. Data on cholesterol-lowering 
in other groups of children are deficient. Indications for 
(including the ages from which medications are approved) 
and the data to support cholesterol-lowering in pediatrics 
are extrapolated from either adult studies, or, for FDA-
approved statins, extrapolated from studies of cholesterol-
lowering in  children with heFH. While it may be possible 
to extrapolate some data, there are other data that it may 
not be  appropriate to extrapolate. For example, dietary 
changes are likely to be more beneficial to children with 
obesity and hypertriglyceridemia, or with other second-
ary causes of dyslipidemia, than to children with primary 
dyslipidemia. Therefore, perhaps, we should expect to use 
lower doses of pharmacological therapies for children with 
secondary dyslipidemia than for those with primary causes. 
But information on side-effect profiles is more likely to 
be similar in both groups. For more information on the 
statin controversies, 2 editorials present equally compel-
ling arguments for therapy and for nonintervention.29,30 
Notwithstanding the discussions, the AHA and the AAP 
both recommend statin therapy.19,22
The 2007 AHA scientific statement on drug therapy of 
high-risk lipid abnormalities in children and adolescents19 
included significant changes compared with the 1998 posi-
tion statement and compared with the NCEP II recommenda-
tions.48 Specifically, the 2007 AHA statement recommended 
the use of statin therapy for children with high-risk lipid 
abnormalities, and statin therapy had not previously been 
recommended.19 The 2007 statement also classified children 
with diabetes as high-risk, suggesting statin therapy at lower 
cholesterol levels.19 There were some caveats included in the 
2007 statement. Firstly, caution should be exercised in ado-
lescent females, as statins are contraindicated in pregnancy 
due to likely teratogenicity. A case series of FDA reports 
of potential teratogenicity following statin therapy analyzed 
HMG-CoA
Statins
Mevalonate
FPP
Squalene Heme A
Cholesterol
GGPP
Isoprenylated proteins:
Rho
Ras
Others
Steroid hormones:
Cell membranes
Myelin formation
Subcellular organelles
Aldosterone
Cortisol
Testosterone
Estradiol
Vitamin D
Ubiquinone
(CoQ10)
Figure 1 Steroid synthesis pathway. inhibition of this steroid pathway by a statin 
(red) may have pleiotropic effects, influencing antioxidant activity (pink); intracellular 
processes (blue), including signal transduction, cell proliferation, and apoptosis; 
structural components (green); and steroid hormones (yellow). Arrows may reflect 
more than one enzyme reaction.
Copyright © 2008 Massachusetts Medical Society. All rights reserved. Reproduced 
with permission from de Ferranti S, Ludwig DS. Storm over statins–the controversy 
surrounding pharmacologic treatment of children. N Engl J Med. 2008;359(13): 
1309–1312.30
Abbreviations: FPP, farnesyl pyrophosphate; GGPP, geranylgeranyl pyrophosphate; 
HMG-CoA, 3-hydroxy-methylglutaryl-coenzyme A.
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52 live births, and identified 20 cases of structural defects, 
including central nervous system and limb abnormalities.49 
Studies such as these must be interpreted in the context of 
mothers who required statin therapy, for example, for diabe-
tes or dyslipidemia, and thus birth defects could potentially 
be attributable to their underlying pathologies rather than 
to statin use. Another cohort study of first trimester women 
taking statins, matched with first trimester women not tak-
ing statins has shown no difference in congenital anomalies 
between the offspring groups.50 However, the women on sta-
tins were younger and their babies lighter than the matched 
controls, and these factors could confound the results. Until 
further studies are available, the consensus is that statins 
should not be prescribed to women of child-bearing age, 
without simultaneous prescription of contraception. One 
clinical approach to this, which might be worth considering 
in the pediatric population, would be recommending con-
traception simultaneously with initiation of statin therapy 
in sexually active female patients, and advising the patient 
regarding teratogenicity, and suggestions to stop statin 
therapy if pregnancy is suspected. It must be remembered 
that the oral contraceptive pill (OCP), one of the forms of 
contraception, is contraindicated in hypertriglyceridemia 
and may be pro-thrombotic in FH. So caution is required if 
considering initiating OCP therapy. A second caveat is that 
statin therapy should only be considered and initiated after 
a male pediatric patient has achieved pubertal development 
Tanner stage II or greater, or after menstruation in female 
pediatric patients, because statins act by interrupting choles-
terol metabolism, and cholesterol is required for all pubertal 
sex steroid hormones. So there is, at least, a theoretical risk 
of statins interfering with puberty.
The AHA scientific statement recommends LDLc at 
which to consider starting therapy and therapeutic targets 
for statin-treated patients (See Table 2).19
Not all statins available in adult medicine are FDA-
approved for pediatric age range patients. And the majority 
of data on which the FDA approvals are based, are data from 
studies of patients with familial hypercholesterolemia and 
other monogenic forms of hypercholesterolemia. Therefore, 
care should be exercised if the clinician chooses to apply 
knowledge acquired from the population of patients with 
familial hypercholesterolemia to a population of patients with 
an entirely different disease etiology, for example, obesity 
and secondary hypercholesterolemia. Also, the FDA approves 
only lower doses of statins for pediatric patients compared 
with approved doses for adult patients.
There are now several systematic reviews and meta- 
analyses51–53 and a Cochrane Database meta-analysis on 
the effect of statins on cholesterol profile in children with 
heFH.54 No study identified an actual ischemic heart disease 
or vascular disease event in the patients studied  during the 
study period. All of these statin studies demonstrate improved 
cholesterol profiles following statin therapy. For example, 
one of the more recent of these meta-analyses estimates that 
LDLc decreases by 1.60 mmol/L (62 mg/dL) (95% confi-
dence interval [95% CI] 1.40–1.80 mmol/L [54–70 mg/dL]), 
HDLc increases by 0.20 mmol/L (7.8 mg/dL) (95% CI 
0.03–0.38 mmol/L [1.2–14.7 mg/dL]), and total cholesterol 
decreases by 3.0 mmol/L (116 mg/dL) (95% CI 2.2–3.8 mmol/L 
[85.4–147.4 mg/dL]).51 Two of these  systematic reviews also 
raise concerns about the inability to comment precisely on 
side-effect profiles, due to nonuniformity of trial reporting 
of and monitoring for side-effects, including interference 
with growth, nutrition, and puberty.51,53 Interestingly, 2 of 
these meta-analyses do report increased growth in the statin-
treated group compared with the placebo-treated group.51,53 
This information on few patients over a maximum 2 years of 
growth is not a sufficient cause for concern at this stage, but 
requires further study. None of these studies identified a dif-
ference in the occurrence of myopathy or increased creatinine 
kinase between statin-treated and placebo-treated groups, but 
meta-analyses were not possible.51 Similarly, meta-analysis of 
liver transaminases was not possible. Although some of the 
individual studies did identify increased aspartate transferase 
and alanine transferase in the statin-treated groups, these 
increases were not statistically significant.51 Risk factors for 
myopathy have been derived from adult data; these risk fac-
tors include advanced age, female sex, low body mass index, 
diminished hepatic and renal function, multiple co-morbidities 
or medications, excess alcohol, intercurrent infections, surgery 
or trauma, drug interactions, and diet. Data from pediatric stud-
ies are scant, but clearly some of the risk factors above are less 
likely to occur in the general pediatric population, including 
advanced age, multiple co-morbidities, and multiple medica-
tions. Given that few pediatric studies have been undertaken, 
it is not possible to comment on the relative efficacy of one 
statin compared with another statin in pediatric patients, and 
Table 2 when to consider starting and therapeutic targets for 
statin therapy19
Consideration to starting therapy:  
LDLc >4.90 mmol/L (190 mg/dL) or;  
LDLc >4.10 mmol/L (160 mg/dL) and patient considered high risk. 
Therapeutic targets after starting therapy: 
LDLc <3.35 mmol/L (130 mg/dL) = minimal target; 
LDLc <2.85 mmol/L (110 mg/dL) = ideal target.
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Table 3 Recommendations for the use of HMG-CoA reductase inhibitors (statins) in children and adolescents with hyperlipidemia
Patient Selection
 1. Begin with the present criteria of the expert panel of the NCeP for drug initiation.
 2.  The age and LDL level at which statin therapy is initiated may be influenced by the presence, magnitude, and number of other cardiovascular risk 
factors, as well as by the presence of cutaneous xanthomas.
 3. include the preferences of patient and family in the decision making.
 4.  in general, do not start before 10 yr of age in boys and preferably after onset of menses in girls. Patients should ideally be at Tanner stage ii  
or higher.
 5. ensure that there are no contraindications for statin therapy (eg, important hepatic disease). 
Initiation and Titration
 1. The choice of the particular statin is a matter of preference.
 2. Start with the lowest dose given once daily, usually at bedtime. Measure baseline CK, ALT, and AST.
 3.  instruct the patient to report all potential adverse effects, especially myopathy (muscle cramps, weakness, asthenia, and more diffuse symptoms) 
immediately. if myopathy is present, its relation to recent physical activity should be assessed, the medication stopped, and CK assessed.  
The patient should be monitored for resolution of the myopathy and any associated increases in CK. Consideration can be given to restarting 
the medication once symptoms and laboratory abnormalities have resolved.
 4. Advise female patients about concerns with regard to pregnancy and the need for appropriate contraception if warranted.
 5.  Advise about drug interactions, especially cyclosporine, fibric acid derivatives, niacin, erythromycin, azole antifungals, nefazadone and many  
HiV protease inhibitors.
 6.  After 4 wks, measure fasting lipoprotein profile, CK, ALT, and AST and compare with laboratory-specific reported normal values.  
The threshold for worrisome CK is 10 times above the upper limit of reported normal; consider impact of physical activity.  
The threshold for worrisome ALT or AST is 10 times above the upper limit of reported normal; consider impact of physical activity.  
Target levels for LDL: minimal, ,3.35 mmol/L (130 mg/dL); ideal, ,2.85 mmol/L (110 mg/dL).
 7. if target LDL levels are achieved and there are no laboratory abnormalities, continue therapy and recheck in 8 wk and then 3 mo.
 8.  if laboratory abnormalities are noted or symptoms are reported, temporarily withhold the drug and repeat blood work in approx. 2 wk.  
when the abnormalities return to normal, the drug may be restarted with close monitoring.
 9.  if target LDL levels are not achieved, double the dose, and repeat the blood work in 4 wk. Continue stepped titration up to the maximum 
recommended dose until target LDL levels are achieved or there is evidence of toxicity.
Monitoring
 1. Monitor growth (height, weight and body mass index and relate to normal growth charts), sexual maturation, and development (Tanner staging).
 2. Monitor fasting lipoprotein profile, CK, ALT, and AST every 3 to 6 mo.
 3.  Monitor and encourage compliance with lipid-lowering dietary and drug therapy. Serially assess and counsel for other risk factors, such as weight 
gain, smoking, and inactivity.
 4.  Counsel adolescent females about statin contraindications in pregnancy and the need for abstinence or use of appropriate contraceptive 
measures. Seek referral to an adolescent medicine or gynecologic specialist as appropriate.
Copyright © 2007 American Heart Association, inc. Reprinted with permission from McCrindle Bw, Urbina eM, Dennison BA, Jacobson MS, Steinberger J, Rocchini AP, 
et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and 
Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation. 2007;115(14):1948–1967.19
Abbreviations: CK, creatine kinase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; LDL, low-density lipoprotein; HMG-CoA, 3-hydroxy-methylglutaryl-
coenzyme A; NCeP, National Cholesterol education Program.
this prevents the possibility of recommending a specific statin. 
Extrapolation from adult data may help, but further pediatric 
studies are required.
The AHA scientific statement gives very specific guide-
lines on initiating and monitoring response to therapy with 
statins. These are summarized in Table 3, which has been 
reproduced from the AHA scientific statement. The AHA 
scientific statement gives exhaustive information on the 
background to these guidelines.19
Type 1 diabetes mellitus is one of the defined high-risk 
conditions in the AHA position statement.19 A large multi-
center RCT is ongoing, evaluating the potential risks and ben-
efits of starting statin therapy in young pediatric patients with 
type 1 diabetes mellitus.55 When considering the argument for 
and against statin use in pediatrics, and using children with 
diabetes as an example, once these children are transitioned 
from pediatric clinics to adolescent or young adult clinics, 
they may be started on statin therapy, and the indications 
for this are largely based on adult studies. While there are 
clear differences between children and adults, the differences 
between adolescents, especially pubertal or postpubertal 
adolescents, and adults are much less clear-cut. If the older 
child, in a pediatric clinic, is postpubertal, and is counseled 
on the risks of teratogenicity and therefore started on OCP 
or another form of contraception and a statin, is there really 
a difference between the adolescent in a pediatric clinic and 
the adolescent in an adult clinic? Perhaps pediatricians are 
justified in their cautious approach to starting statins in young 
children, but in older adolescents, who are pubertal, perhaps 
this caution is not equally justified. As with all therapies 
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initiated in pediatric populations, this should be discussed 
with the child and the parents, and their concerns taken into 
consideration.
ezetimibe
Ezetimibe selectively inhibits absorption of cholesterol at 
the small intestinal brush border. In selectively inhibiting 
cholesterol absorption, ezetimibe does not inhibit absorp-
tion of TG or fat-soluble vitamins. The cholesterol-lowering 
effectiveness of ezetimibe has been documented in several 
trials, in several groups of patients, including those with 
hoFH,56 polygenic hypercholesterolemia,57 heFH,57 and 
familial combined hyperlipidemia.58 In each of these studies, 
ezetimibe appeared to be very well tolerated, with no identi-
fied problems with growth or pubertal development.
These studies show clearly the effectiveness of ezetimibe 
in reducing cholesterol, without significant side-effects iden-
tified. However, the problem, previously discussed, about 
cholesterol-lowering efficacy being distinct from reduction 
in cardiovascular risk, cardioprotection, and reduction in 
end-points of vascular and cardiovascular disease, is again 
emphasized by recent studies on ezetimibe. A recent study, 
Effect of Combination Ezetimibe and High-Dose Simvastatin 
versus Simvastatin alone on the Atherosclerotic Process in 
Patients with Heterozygous Familial Hypercholesterolemia, 
demonstrated no improvement in CIMT with combined 
simvastatin and ezetimibe therapy, and no increase in HDLc 
with ezetimibe therapy.59 However, the results of this study 
are difficult to apply to other populations of patients, as only 
patients with normal CIMT were selected for inclusion in 
this study. A further study, Simvastatin and Ezetimibe in 
Aortic Stenosis trial, identified higher cancer incidence and 
higher rates of death from cancer over a 4-year period in 
adult patients treated with ezetimibe than those treated 
with simvastatin (9.9% vs 7.0%, P = 0.03 and 4.1% vs 
2.5%, P = 0.05, respectively).60 The analyses did not reveal 
an increase in any specific cancer, or any change in can-
cer incidence with duration of statin therapy. We do not 
know of any similar reports of malignancies in children 
treated with ezetimibe. Care needs to be exercised when 
extrapolating these results to pediatrics, as malignancies are 
more common in adults than in children, and furthermore, 
malignancies are more likely to be identified sooner in adult 
patients enrolled in trials than in those not enrolled in tri-
als. Nonetheless, the results of this study carry a warning 
to clinicians. The results of these 2 trials are disappointing 
in light of other studies. An ongoing large, multicenter 
trial, Improved Reduction of Outcomes: Vytorin Efficacy 
International Trial (IMPROVED-IT), which aims to compare 
the cardioprotection of simvastatin alone and combined sim-
vastatin with ezetimibe, may help to resolve the discrepancies 
between these studies to date.61 However, we agree with 
other authors, who have called for further studies examining 
specifically the effectiveness and side-effects in pediatric 
patients.51,62 We think that these future studies should take 
the form of either large multicenter RCTs, databases, or both, 
to record the progress of all patients treated with ezetimibe. 
We also suggest that future studies should aim to standardize 
the cholesterol, endocrine, metabolic, and vascular function 
outcomes being recorded, as well as recording any potential 
development of malignancies on therapy.
Bile acid resins
While bile acid resins were one of the first pharmacological 
therapies used in hypercholesterolemia, their use has been 
supplanted by newer pharmaceutical agents, largely due to 
the frequency and severity of gastrointestinal side-effects 
( primarily abdominal pain and nausea). Bile acid resins 
include colestipol and cholestyramine. They act by bind-
ing to intestinal bile acids, preventing the reabsorption and 
 recirculation of bile acids, resulting in intestinal excretion 
of bile salts, with a consequent increase in conversion of 
cholesterol to bile salts. There is a consequent reduction 
in hepatic cholesterol, an increase in LDL receptors, and 
an overall reduction in the circulating cholesterol pool. 
Cholestyramine was studied in a landmark RCT in 1984, 
and was found to reduce cholesterol by 8.5%, compared 
with placebo.63 Furthermore, an observational subanalysis of 
the cholestyramine-treated group showed a dose-dependent 
relationship between the amount of cholesterol reduction 
achieved and the reduction in risk of coronary heart dis-
ease.64 However, due to side-effects and lack of tolerability, 
as well as the use of new alternatives, these drugs fell into 
disuse.
However, colesevelam hydrochloride, a newer bile acid 
resin, was recently trialed in children with heFH.65 Coleseve-
lam was given either alone or in combination with a statin. 
Colesevelam resulted in decreased LDLc and compliance 
was good, with few complaints of side-effects. Following this 
trial, various authors expect that interest in bile acid resins 
will increase.24 Furthermore, colesevelam is FDA approved 
for lowering HbA
1c
 and may be valuable for use in patients 
with diabetes. Of particular note, FDA approval for pediatric 
use of bile acid resins was never achieved. However, potential 
future studies, if they produce results similar to Stein’s recent 
trial,65 may result in approval in the future.
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Niacin and fibrates
Niacin is a hydrophilic B complex vitamin, which increases 
HDLc levels and reduces very low-density lipoprotein cho-
lesterol (VLDLc) levels, by reducing production and release 
of VLDLc by the liver. Niacin is sometimes prescribed for 
pediatric patients with hoFH, a condition which is associated 
with symptomatic ischemic heart and vascular disease at 
very young ages.66 Niacin may also be prescribed for patients 
with increased lipoprotein A and a history of cerebrovascular 
accidents.66 Niacin is not commonly used in pediatric patients 
with other conditions or other causes of hypercholester-
olemia, and data on its efficacy are limited. Known potential 
side-effects of niacin include flushing, impaired glucose 
tolerance, liver failure, and myopathy.
Fibrates and fenofibric acid (fenofibrate) derivatives 
act on lipid metabolism by activating the peroxisome 
proliferator-activated receptor-alpha (PPAR-α) and act on 
the metabolism of TG and HDLc through several pathways 
including: reducing plasma TG levels by inhibiting their 
synthesis and stimulating their clearance; decreasing both 
apo C II and apo C III expression in the liver via PPAR-α 
activation, and thus delaying the catabolism of TG; and 
increasing HDLc levels by increasing hepatic apo A I and 
II synthesis.
Fibrates have been the primary pharmacologic agent 
to target primary hypertriglyceridemia.19,67 The efficacy 
and safety of fibrates in the children population have 
been demonstrated,68 but additional pediatric studies 
suggest that these drugs may be unable to decrease TG 
levels  sufficiently.69 One group of authors has suggested 
an incremental approach to pharmaceutical treatment of 
pediatric hypertriglyceridemia: 1) Use of 3 fatty acids or 
medium-chain TG; 2) Addition of a cholesterol-lowering 
medication; 3) Use of fibrates if this combination fails to 
reduce TG.70
Final statement on  
pharmacological therapy
Currently, statins are the recommended first-line pharmaco-
logical therapy for children with hyperlipidemia, in whom 
sufficient diet and lifestyle modifications have not sufficiently 
reduced cholesterol measures. Ongoing studies are examining 
other pharmacological therapies, both as monotherapies and 
in combination with other therapies including statins. We do 
not know what the future holds, in terms of future reviews of 
current recommendations. But clinicians who prescribe sta-
tins should be aware of the potential and debated side-effects, 
and should monitor closely for these, and for unsuspected 
side-effects. At all times, and with all therapies, the patient 
and parents must be supported and encouraged to make 
continuous diet and lifestyle modifications.
Future directions
The ongoing debates about statins or other therapy for 
children and adolescents are healthy debates, and should 
continue, until such time as large multicenter databases and 
RCTs address the issues of efficacy and safety of statins 
and other cholesterol-lowering therapy in children. How-
ever, when faced with an individual patient, therapy should 
be individualized to that patient, and should, therefore, 
address risk and benefit profiles in that individual patient. 
If therapy is initiated, regular follow-up with monitoring of 
cholesterol levels, side-effects, and growth, nutrition, and 
puberty are essential. It is the duty of the clinician, as well 
as parents and society at large, to ensure that the child’s or 
adolescent’s therapy includes ongoing dietary and lifestyle 
intervention and monitoring, even and especially after start-
ing pharmacological therapy. Finally, if one of the outcomes 
of the debate on statins and other cholesterol-lowering 
therapies in children and adolescents is modification of 
environmental and societal diet and lifestyle, then future 
generations of  children, and adults, can only benefit. Large 
multicenter RCTs and databases for children on statins and 
other cholesterol-lowering therapies should be initiated, so 
that information on children attending all pediatric centers, 
large and small, can be entered and recorded to inform 
future studies and policies. Policy-makers can be lobbied, 
and if persuaded that interventions in childhood may modify 
diseases in adulthood, then governmental or federal fund-
ing may be made available. Funding from pharmaceutical 
industry, if available, should be used only if the funding is 
ethical and independent of any influences on study design 
or outcomes (indications for prescription and choice of 
medications recommended, etc). Consideration of screen-
ing is important, and should be instituted whether targeted 
or universal. This might be conducted simultaneously with 
vaccination or adolescent health assessments, dependent on 
local policies for medical examination of healthy children 
and adolescents. However, consensus needs to be achieved 
by all parties, on the indications for and benefits of interven-
tions for dyslipidemia in childhood. For this to be achieved, 
ongoing pediatric studies are required.
Summary
There is significant evidence that atherosclerosis has its 
origins in childhood. While medications have proven benefit 
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in cholesterol reduction in children and adolescents, there 
have not been sufficient data proving benefit in improve-
ment in endothelial function, or other improvements in 
cardiovascular end-points. This is a problem germane to 
diseases that begin in childhood, but manifest disease only 
in adulthood, meaning that only surrogate markers of dis-
ease are amenable to pediatric studies. Large multicenter 
databases, RCTs, and long-term epidemiological studies 
following treated and untreated children into adulthood, 
should help to address the remaining questions. In the 
interim, the AHA19 and the AAP22 have endorsed statin 
therapy as first-line therapy for pediatric hyperlipidemia, 
after suff icient diet and lifestyle changes have been 
effected, in children of 8 years and older, who have entered 
Tanner II puberty (for males) and have had menarche (for 
females). The FDA has approved the use of statins for 
children of 8 to 10 years and older with heFH. There is 
no incontrovertible evidence of impaired growth, pubertal 
development, or cognitive development with statin therapy 
to date. Statins are potentially teratogenic, thus requiring 
extra caution, and perhaps consideration of simultane-
ous prescribing of the oral contraceptive pill in females 
of child-bearing years. Finally, pharmacological therapy 
should not be prescribed without taking every opportunity 
to continuously encourage adherence to healthy diet and 
lifestyle choices. We encourage caution in clinicians who 
are considering prescribing statin therapy, and we urge that 
parents and patients be appraised fully of the risks and the 
current debates on this topic.
It appears that RL Holman was correct: atherosclerosis is 
“a pediatric problem”. The recent additional information 
is that the identification of the correct therapy in pediatrics 
is also “a pediatric problem” – and the ideal solution to the 
problem remains to be identified and agreed upon by all 
concerned pediatricians.1
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